Catalyst Pharmaceuticals (CPRX) Cash from Investing Activities (2011 - 2026)
Catalyst Pharmaceuticals (CPRX) reported Cash from Investing Activities of -$27000.0 for Q1 2026, up 15.62% quarter-over-quarter from -$32000.0 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Catalyst Pharmaceuticals has reported Cash from Investing Activities for 16 years, with the latest figure at -$27000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$27000.0; the trailing twelve-month figure through Mar 2026 stood at -$85000.0 (up 76.19% YoY), and the FY2025 full-year result was -$58000.0, up 89.57% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$27000.0, up from -$32000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$10000.0 in Q2 2024, with the low at -$162.4 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged -$26.8 million across 5 years, with a median of -$132000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 70215.91% — and 2024, when it jumped 99.88%.
- Catalyst Pharmaceuticals' Cash from Investing Activities stood at -$132000.0 in 2022, then plunged by 28928.79% to -$38.3 million in 2023, then surged by 99.77% to -$88000.0 in 2024, then jumped by 63.64% to -$32000.0 in 2025, then climbed by 15.62% to -$27000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$27000.0 (Q1 2026), -$32000.0 (Q4 2025), and -$26000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Catalyst Pharmaceuticals | 3.84 Bn | 3.08 Bn | 134.92 Mn | -27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Sep 30, 2024 | -259,000.00 |
| Sep 30, 2024 | -259,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -199,000.00 |
| Mar 31, 2024 | -199,000.00 |
| Dec 31, 2023 | -38.32 Mn |
| Dec 31, 2023 | -38.32 Mn |
| Sep 30, 2023 | -92.82 Mn |
| Sep 30, 2023 | -92.82 Mn |
| Mar 31, 2023 | -162.37 Mn |
| Mar 31, 2023 | -162.37 Mn |